KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) EPS (Weighted Average and Diluted) (2018 - 2025)

CRISPR Therapeutics AG's EPS (Weighted Average and Diluted) history spans 8 years, with the latest figure at -$1.32 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 214.29% year-over-year to -$1.32; the TTM value through Dec 2025 reached -$6.47, down 48.74%, while the annual FY2025 figure was -$6.47, 49.08% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$1.32 at CRISPR Therapeutics AG, down from -$1.17 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $9.44 in Q2 2021 and bottomed at -$2.4 in Q2 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$1.42 (2023), against an average of -$0.83.
  • The largest annual shift saw EPS (Weighted Average and Diluted) soared 826.15% in 2021 before it tumbled 214.29% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.74 in 2021, then grew by 19.54% to -$1.4 in 2022, then surged by 180.71% to $1.13 in 2023, then crashed by 137.17% to -$0.42 in 2024, then crashed by 214.29% to -$1.32 in 2025.
  • Per Business Quant, the three most recent readings for CRSP's EPS (Weighted Average and Diluted) are -$1.32 (Q4 2025), -$1.17 (Q3 2025), and -$2.4 (Q2 2025).